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Abstract 23 
Objectives: OXA-48-like carbapenemases have spread worldwide since 2001. We analysed 24 
patient and microbiological data for UK isolates with these enzymes as confirmed by the 25 
national reference laboratory from November 2007 - December 2014. 26 
Methods: MICs were determined using BSAC agar dilution. Isolates with reduced 27 
susceptibility or resistance to 1 carbapenem and high-level resistance to both 28 
piperacillin/tazobactam (MIC > 64 mg/L) and temocillin (MICs ≥ 128 mg/L) were screened by 29 
PCR for blaOXA-48-like genes. The genomes of around half of the isolates were sequenced, 30 
with MLST types, resistance genes and plasmid replicon types inferred. Patient data 31 
provided by sending laboratories were reviewed. 32 
Results: Isolates (n=741) with OXA-48-like carbapenemases were submitted from 111 UK 33 
laboratories, representing 536 patients. Almost all (99%; 736/741) were Enterobacteriaceae, 34 
predominantly Klebsiella pneumoniae (55%; 408), and most (80%; 595) were from 35 
inpatients. WGS of 351 non-duplicate isolates identified blaOXA-48 as the most common 36 
variant, found in two-thirds (235/351) of isolates, followed by blaOXA-181 (68), blaOXA-232 (32), 37 
blaOXA-244 (10), blaOXA-484 (5) and blaOXA-245 (1). Among K. pneumoniae (163/351), E.coli 38 
(114/351), and E. cloacae (42/351), 119 STs were identified. Mapping analyses revealed 39 
that 63% (222/351) of isolates harboured plasmids that shared >99% identity to one of four 40 
known plasmids; pOXA-48a (44%; 154/351), pOXA-232 (10%; 34/351), pOXA181 (9%; 41 
30/351), and pKP3-A (1%; 4/351); the remaining 37% of isolates harboured blaOXA-48-like in 42 
unknown environments. 43 
Conclusions: OXA-48-like carbapenemases are an increasing problem in the UK. This 44 
study highlights both the role of successful plasmids and polyclonal nature of their 45 
dissemination.  46 
Introduction 47 
OXA-48-type carbapenemases were first identified in 2001 in a carbapenem-resistant 48 
Klebsiella pneumoniae isolate from the urine of a patient hospitalised in Istanbul, Turkey.1 49 
Since then, reports of infections caused by OXA-48-producing Enterobacteriaceae have 50 
escalated - particularly in Europe, Asia and Africa, and less so in the Americas.2-5 There are 51 
six carbapenem-hydrolysing class D beta-lactamase (CHDL) subgroups that are clinically 52 
significant; OXA-23, OXA-24/40, OXA-48, OXA-51, OXA-58, and OXA-143.6 All except the 53 
OXA-48 group are predominantly found in Acinetobacter spp. isolates,6 whereas OXA-48 54 
enzymes are usually found in Enterobacteriaceae.5 To date, 14 OXA-48-like variants have 55 
been described (OXA-48, -162, -163, -181, -199, -204, -232, -244, -245, -247, -370, -405, -56 
436, and -484) of which 11 are CHDLs. These vary in sequence by one to five amino acids 57 
from the ‘classical’ OXA-48 variant and hydrolyse penicillins and carbapenems but not 58 
extended-spectrum cephalosporins (e.g. cefepime and ceftazidime).1 In contrast to their 59 
CHDL counterparts, OXAs -163, -247 and -405 also differ from OXA-48 by one or two amino 60 
acids but additionally have a four-amino-acid deletion in the active site region: as a result 61 
they lack significant carbapenemase activity but do exhibit increased activity toward 62 
extended-spectrum cephalosporins.7-9  63 
blaOXA-48 has only been found in Enterobacteriaceae, and has been associated with 64 
outbreaks in Turkey, the Middle East and North Africa.5, 10 Other variants have different 65 
geographical associations: in particular blaOXA-181 and blaOXA-232 have been epidemiologically 66 
linked to the Indian subcontinent and are often co-harboured with NDM enzymes.11, 12 67 
The proliferation of OXA-48-like enzymes has been attributed both to successful clones and 68 
to plasmid spread. In 2011, OXA-48-positive K. pneumoniae ST395 was identified in patients 69 
in Morocco, the Netherlands and France, suggesting the country-to-country transfer of this 70 
clone,13 with patient-linked transfer of OXA-48-producing Enterobacter cloacae from 71 
Morocco to France also documented.14 On the other hand, pOXA-48a, a 61.9 kb self-72 
conjugative IncL/M plasmid, was shown to be the primary vehicle for dissemination of blaOXA-73 
48 in several outbreaks.5, 15 This broad-host-range plasmid harbours blaOXA-48 within Tn1999 74 
and occurs across several enterobacterial species.5, 15  75 
This study describes the epidemiology of OXA-48-like carbapenemase producers submitted 76 
to PHE’s Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) 77 
Reference Unit between 2007 and 2014.  78 
 79 
Materials and Methods 80 
Bacterial isolates, identification and susceptibility testing 81 
Isolates were submitted to PHE’s AMRHAI Reference Unit from clinical laboratories across 82 
the UK between November 2007 and December 2014 for investigation of unusual 83 
resistance, including to carbapenems.   84 
Bacterial identification was carried out using chromogenic agars [CHROMagar™ Orientation 85 
(CHROMagar, Paris, France) and Brilliance UTI (Oxoid, Basingstoke, UK)] together with 86 
API-20E tests (bioMérieux SA, Marcy-l'Étoile, France) or, since August 2012, by matrix-87 
assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS; 88 
Bruker Microflex LT, Bruker Daltonik GmbH, Bremen, Germany).  89 
Antibiotic susceptibilities (MICs) were determined by BSAC agar dilution16 using AMRHAI's 90 
standard Gram-negative antibiotic panel, which includes ertapenem, meropenem and 91 
imipenem (the latter with/without 320 mg/L EDTA to detect metallo-carbapenemases), and 92 
interpreted using EUCAST breakpoints.17 93 
 94 
Screening for carbapenemase genes 95 
Isolates displaying high-level resistance to piperacillin/tazobactam (MICs 64 mg/L) and 96 
temocillin (MICs 128 mg/L), as well as reduced susceptibility or resistance to any 97 
carbapenem were tested for blaOXA-48-like genes  by in-house PCR1 and/or with a commercial 98 
microarray (Check-MDR CT102; Check-Points, Wageningen, The Netherlands).18 In 99 
instances where imipenem potentiation by EDTA was observed, isolates were also tested by 100 
PCR for the presence of metallo-carbapenemases (blaNDM, blaVIM, blaIMP, blaGIM, blaSIM and 101 
blaSPM) by in-house PCRs.19  102 
 103 
Whole Genome Sequencing (WGS) and analyses 104 
Three hundred and seventy isolates, temporally and geographically distributed throughout 105 
the study, were selected for WGS. Genomes were sequenced using the Nextera sample 106 
preparation method with the standard 2 × 100-base sequencing protocols on a HiSeq 107 
instrument (Illumina, San Diego, CA, USA). Data were analysed using an in-house 108 
bioinformatics pipeline as previously described.20 Sequence types (STs) were inferred from 109 
WGS data where MLST schemes exist.   110 
For plasmid analysis, sequencing reads were mapped against known OXA-48 plasmids, 111 
namely pOXA-48a (NC_019154), pOXA-232 (JX423831), pKP3-A (NC_019160), and 112 
pOXA181 (KP400525). 113 
 114 
Analysis of patient demographic information 115 
Patient data were obtained from the request forms sent with submissions from referring 116 
laboratories. A patient was categorized as ‘new’ if they were found to have OXA-48-like-117 
positive isolates detected by AMRHAI for the first time and ‘known’ if any OXA-48-like-118 
positive isolate, irrespective of species, had previously been identified from the patient by 119 
AMRHAI. 120 
Results 121 
Demographics of patients affected and distribution 122 
During the study period, AMRHAI confirmed 741 OXA-48-like positive isolates from 111 123 
laboratories throughout the UK and obtained from 536 patients. Figure 1 illustrates the 124 
temporal distribution of these isolates among ‘new’ and ‘known’ patients, and among 125 
submitting laboratories. The first OXA-48-like positive isolate was a K. pneumoniae, 126 
submitted to AMRHAI in November 2007 and obtained from the urine of a patient previously 127 
hospitalised in Turkey.10  128 
Isolates with OXA-48-like carbapenemases were submitted from laboratories across all UK 129 
regions. The national distribution of affected patients was as follows: England (n=514), 130 
Scotland (n=13), Northern Ireland (n=6), and Wales (n=3). The greatest number of affected 131 
patients was in the London region (n=203), followed by the North West (n=143).  132 
Most source patients were hospitalized (79%; 421/536) but a few were outpatients (7%; 133 
38/536), in primary care (8%; 41/536) or in unknown settings (7%; 36/536). The mean 134 
patient age was 59.5 years and 54% (289/536) were male. 135 
A travel history was reported for 130/536 (24%) patients. Of these, 55 patients had 136 
documented foreign travel to the following destinations; India (12), Turkey (9), Pakistan (5), 137 
Egypt (4), Libya (4), Spain (4), Kuwait (3), Malta (3), Sri Lanka (2), Tunisia (2) and single 138 
patients had travelled to Cyprus, Kenya, Morocco, Russia, Saudi Arabia, Singapore, and 139 
Syria. Twenty patients were known to have been hospitalised whilst abroad in Egypt (4), 140 
Libya (4), Turkey (4), India (3), Pakistan (2), Cyprus (1), Spain (1) and Sri Lanka (1). 141 
Single OXA-48-like-positive isolates were referred from 408/536 (76%) patients and multiple 142 
isolates from the remaining 128 (24%). Amongst the patients with multiple OXA-48-like-143 
positive isolates, 43/128 (34%) yielded isolates of different species or genera and 63/128 144 
(49%) had isolates referred from different anatomical sites. The OXA-48-like-positive isolates 145 
were referred over a period of <14 days in 65/128 (51%) instances, for 17/128 over a period 146 
of 14 to 28 days, 38/128 over a period of 1 to 6 months and over a period >6 months from 8 147 
patients. Seventeen percent (127/741) of isolates were submitted from a single laboratory 148 
(laboratory 1), which serves 3 hospitals (to be subsequently known as hospitals A, B and C), 149 
over a 2-year period. Further details of the isolates from this laboratory are given below. 150 
 151 
Microbiology 152 
Most (99%; 736/741) submitted isolates were Enterobacteriaceae, comprising: K. 153 
pneumoniae (55%; 408/741), E. coli (29%; 218/741), Enterobacter spp. (9%; 68/741), 154 
Klebsiella oxytoca (3%; 24/741), Citrobacter spp. (2%; 14/741), Serratia marcescens (>1%; 155 
3/741) and one Raoutella ornithinolytica. There were also five non-Enterobacteriaceae 156 
isolates comprising: Pseudomonas aeruginosa (n=3; all from one patient)21 and Shewanella 157 
spp. (n=2; OXA-48-like enzymes are intrinsic in this genus). 158 
If samples, rather than patients were considered as the denominator, most were taken in 159 
hospitals (89%; 656/741), but some were general practice urines (6%; 45/741) and a few 160 
from unknown settings (5%; 40/741). The most frequently reported specimen type was urine 161 
(29%; 215/741), followed by faeces/rectal swabs (27%; 202/741). Fifteen percent (110/741) 162 
of isolates were obtained from tissue and fluid samples, 11% (83/741) from blood cultures 163 
and line tips, 9% (68/741) from screening swabs, 5% (40/741) from respiratory samples, and 164 
3% (23/741) were unknown specimen types (Table 1). 165 
 166 
Carbapenemase alleles and typing of the isolates  167 
WGS was undertaken for 351 non-duplicate isolates from single patients and their STs 168 
(where MLST schemes exist) and carbapenemase alleles were defined. These comprised: 169 
K. pneumoniae (n=163), E. coli (n=114), E. cloacae (n=42), K. oxytoca (n=13), Citrobacter 170 
spp. (n=11), other Enterobacter spp. (n=5), S. marcescens (n=2), and P. aeruginosa (n=1). 171 
Their carbapenemase genes comprised: blaOXA-48 (66%; 230/351), blaOXA-181 (18%; 62/351), 172 
blaOXA-232 (7%; 24/351), blaOXA-244 (3%; 10/351), blaOXA-245 (<1%; 1/351), blaOXA-484 (1%; 173 
5/351), blaOXA-48 + blaNDM-1 (1%; 5/351), blaOXA-181 + blaNDM-1 (2%; 6/351) and blaOXA-232 + 174 
blaNDM-1 (2%; 8/351). The carbapenemase variants and allele combinations OXA-48, OXA-175 
181, OXA-48 + NDM-1, and OXA-181 + NDM-1, were found in multiple species. OXA-232, 176 
OXA-245, OXA-484, and OXA-232 + NDM-1 were found only in K. pneumoniae isolates, 177 
whilst OXA-244 was found only in E. coli isolates. Numerous other genes encoding 178 
resistance to several other classes of antibiotics were also detected throughout all species 179 
(Table 2). Overall, 19/351 (5%) isolates had OXA-48-like enzymes together with another 180 
carbapenemase, 266/351 (76%) also harboured a predicted extended-spectrum beta-181 
lactamase or plasmid-encoded AmpC, and 85/351 (24%) had OXA-48-like enzymes without 182 
any of these additional beta-lactamase types.   183 
 184 
K. pneumoniae 185 
One hundred and sixty-three non-duplicate K. pneumoniae isolates, from 56 laboratories 186 
across 10 UK regions, were sequenced. Individual laboratories submitted between 1 and 15 187 
isolates. Forty-nine STs were identified, the most frequent being ST14 (27 isolates from 17 188 
centres over 16-months), followed by ST231 (18 from 14 centres over 15-months), ST147 189 
(17 from 13 centres over 7-years), ST101 (13 from 10 centres over 4-years), ST11 (10 from 190 
7 centres over 16-months) and ST16 (6 from 5 centres over 3-months). The remaining 43 191 
STs were each represented by five isolates or fewer. Five OXA-48-like variants were 192 
identified: blaOXA-48 (n=86), blaOXA-181 (n=31), blaOXA-232 (n=24), blaOXA-484 (n=5) and blaOXA-245 193 
(n=1), and 16 isolates produced more than one carbapenemase: blaOXA-48 + blaNDM-1 (n=3), 194 
blaOXA-181 + blaNDM-1 (n=5), and blaOXA-232 + blaNDM-1 (n=8).    195 
Multiple plasmid replicon types were identified including IncL/M, IncA/C, several IncF 196 
variants, IncHI2, IncX3 and ColE-like replicons. Plasmid mapping revealed that 70/86 (81%) 197 
of isolates with OXA-48-enzymes and one with OXA-245 had plasmids exhibiting >99% 198 
sequence identity to pOXA-48a, whereas among the 31 with OXA-181-enzymes 8 (26%) 199 
and 5 (16%) had plasmids with >99% sequence identity to pOXA181 and pKP3-A, 200 
respectively.  All 32 isolates with OXA-232 enzymes had plasmids exhibiting >99% 201 
sequence identity to pOXA-232. pOXA-48a sequences were found in 37 STs, most 202 
frequently ST11 (n=8) and ST101 (n=9) whereas pOXA181 sequences were found in 5 STs 203 
(ST11, ST61, ST25, ST307, and ST709), each with 1-3 representatives; whilst pKP3-A 204 
sequences were found in 2 STs with one (ST395) and four representatives (ST147) 205 
respectively. pOXA-232 sequences were found in 7 STs (ST14, ST15, ST16, ST147, ST231, 206 
ST307 and ST395), most often ST14 (15 isolates from 13 centres), ST231 (11 from 8 207 
centres), and ST147 (3 from 2 centres).  208 
The earliest UK isolate with an OXA-48-like enzyme dated from 2007 and was from a patient 209 
who had previously been hospitalised in Turkey.10 It was shown here to belong to ST147 and 210 
to harbour a pOXA-48a-like plasmid. 211 
The most frequent submitter, laboratory 1, sent 15 isolates that were subjected to WGS over 212 
22-months – 13 of which were obtained from hospital A. These fifteen represented 11 STs 213 
and all harboured plasmids with >99% sequence identity to pOXA-48a.  214 
 215 
E. coli 216 
One hundred and fourteen non-duplicate E. coli isolates, from 49 laboratories across 7 UK 217 
regions, were sequenced. Laboratories submitted between 1 and 16 isolates and 37 STs 218 
were identified. The most frequent of these were ST38 (53 isolates from 34 laboratories over 219 
42-months) and ST410 (12 from nine laboratories over 20-months). The remaining 35 STs 220 
were each represented by four isolates or fewer. Three OXA-48-like variants were identified; 221 
blaOXA-48 (n=74), blaOXA-181 (n=30), and blaOXA-244 (n=10).  222 
Multiple plasmid replicon types were identified including IncL/M, several IncF replicons, 223 
IncB/O, IncHI2, IncK and IncX3.  Plasmid analyses revealed that 22/74 (30%) of E. coli with 224 
OXA-48-enzymes had plasmids exhibiting >99% sequence identity to pOXA-48a, and 22/30 225 
(73%) of those with OXA-181 had plasmids that exhibited >99% sequence identity to 226 
pOXA181. pOXA-48a sequences were found in 17 STs, each with 1-4 representatives. 227 
pOXA181 sequences were found in 10 STs, predominantly ST410 (n=11) which were 228 
submitted from 8 laboratories across 5 regions. No plasmid could be identified in 70 isolates.  229 
Of these, 50 belonged to ST38, 41 of them harbouring blaOXA-48 and nine harbouring blaOXA-230 
244. The most frequent submitter, laboratory 1, sent 16 isolates that were subject to WGS 231 
over a 21-month period - 14 of which were obtained from hospital A; these represented 14 232 
STs, all had OXA-48 and 12/16 (75%) harboured pOXA-48a sequences. 233 
 234 
Enterobacter spp. 235 
Forty-seven non-duplicate Enterobacter spp. isolates, sent from 15 laboratories across 7 UK 236 
regions, were sequenced. These comprised; E. cloacae (n=42), E. aerogenes (n=4) and E. 237 
hormaechei (n=1). Individual laboratories submitted between 1 and 27 isolates. Forty-five 238 
isolates harboured blaOXA-48 and the remaining 2 isolates harboured blaOXA-48 + blaNDM-1. 239 
Thirteen STs were identified among the E. cloacae isolates, each with between 1 and 17 240 
representatives. The most frequently obtained ST was ST108 (17 isolates from 2 centres 241 
over 15-months), the remaining 12 STs were represented by 5 isolates or fewer. Multiple 242 
plasmid replicon types were identified including IncL/M, IncN, IncHI1 and several IncF 243 
replicons. Plasmid mapping revealed that 42/47 (89%) of isolates had DNA exhibiting >99% 244 
sequence identity to pOXA-48a. These comprised 40 E. cloacae, and single isolates of E. 245 
aerogenes and E. hormaechei. Thirteen STs were identified among the 40 E. cloacae 246 
isolates but predominantly ST108 with 17 representatives. Most were submitted (16/17) from 247 
laboratory 1 and 14/16 were obtained from hospital A, over a 3-month period. Fifteen of 248 
these 16 (94%) harboured pOXA-48a sequences. In total, over half (27/48) of the 249 
Enterobacter spp. isolates with OXA-48-like enzymes were submitted by laboratory 1 over a 250 
15-month period – 25 of which were obtained from hospital A, with these comprising 25 E. 251 
cloacae and one E. hormaechei. All 26 isolates produced OXA-48 and the 25 E. cloacae 252 
isolates represented 5 STs. 253 
 254 
K. oxytoca 255 
Thirteen non-duplicate K. oxytoca isolates, sent from 7 laboratories across 4 UK regions, 256 
were sequenced, with individual laboratories submitting between 1 and 4 isolates. All 257 
harboured the classical blaOXA-48 variant. Five STs were identified, namely ST176 (6 isolates 258 
from 5 centres in four regions), ST27 (4 from one centre in one month), along with single 259 
representatives of ST36, ST95 and ST168. Multiple plasmid replicons were identified 260 
including IncL/M, IncHI2 and several IncF replicons. Plasmid mapping analyses revealed 261 
that all isolates shared >99% sequence identity with plasmid pOXA-48a. 262 
 263 
Other species 264 
The remaining 14 isolates that were sent for WGS comprised: Citrobacter freundii (n=9), 265 
Citrobacter koseri (n=2), S. marcescens (n=2) and P. aeruginosa (n=1). All harboured 266 
classical blaOXA-48 except for one C. freundii isolate, which harboured blaOXA-181 + blaNDM-1, 267 
and the P. aeruginosa isolate that had blaOXA-181. The P. aeruginosa isolate was previously 268 
found to belong to ST773 with blaOXA-181 encoded within Tn2013.21 Plasmid replicon types 269 
included IncL/M, several IncF replicons and IncA/C. Within the 9 C. freundii isolates 8 STs 270 
were identified. Five of these were obtained from inpatients in hospital A, 3 of which 271 
harboured pOXA-48a sequences.  In the remaining isolates 2 C. koseri isolates which 272 
produced OXA-48 shared >99% identity to plasmid pOXA-48a, and one OXA-181 producing 273 
C. freundii isolate shared >99% identity to pKP3-A.  274 
 275 
Antibiotic susceptibility 276 
MIC distributions for OXA-48-like-positive isolates are shown in Table 3. Ninety-nine percent 277 
(724/728) of isolates with available susceptibility data were resistant or non-susceptible to 278 
ertapenem; however 42% (312/735) and 54% (400/735) remained susceptible to imipenem 279 
and meropenem, respectively, based on EUCAST breakpoints. In all but 8 cases, MICs of 280 
meropenem were above the EUCAST screening cut-off concentration of 0.125 mg/L.22 For 281 
the remaining 8 cases the imipenem MICs were also below the EUCAST screening cut-off of 282 
1 mg/L but were above the ertapenem MIC cut-off of 0.125 mg/L. All 8 isolates were E. coli 283 
and analysis of 7/8 by WGS indicated that 6 different STs and 2 OXA-48-like variants 284 
(blaOXA-48 (5) and blaOXA181 (2)) were represented. Piperacillin/tazobactam resistance (MIC 285 
>16 mg/L) was observed in 732/734 of tested isolates (data not shown). All the isolates that 286 
co-produced either NDM or VIM enzymes were non-susceptible to all three carbapenems. 287 
Non-susceptibility to ceftazidime and cefotaxime was observed in 69% and 89% of isolates. 288 
Non-susceptibility to the aminoglycosides amikacin, gentamicin and tobramycin was 289 
observed in 26%, 55% and 61% of isolates, respectively. Almost all (28/34) isolates that co-290 
produced another carbapenemase were non-susceptible to all 3 aminoglycosides and all 291 
were resistant to ciprofloxacin. Most (91%; 659/722) isolates were susceptible to colistin.  292 
Colistin resistance was observed in 63 isolates, submitted from 32 laboratories over 6 years, 293 
the majority (54/63) of which were K. pneumoniae and had MICs in the range to 4->32 mg/L. 294 
Sequencing of 21/54 colistin resistant K. pneumoniae isolates identified 9 STs, 6 of which 295 
were represented by a single isolate and the 4 remaining STs were as follows: ST14 (6), 296 
ST101 (4), ST147 (2), and ST231 (4). These 21 were submitted from 14 laboratories across 297 
5 regions. For 10 isolates colistin MICs were >32mg/L; these comprised 7 K. pneumoniae 298 
and one E. coli along with two S. marcescens with inherent resistance. These were referred 299 
from 10 laboratories across 4 regions. Non-susceptibility to ciprofloxacin and tigecycline was 300 
observed in 63% and 32% of isolates, respectively. 301 
 302 
Discussion 303 
This report reviews all isolates producing an OXA-48-like carbapenemase and referred to 304 
PHE’s AMRHAI Reference Unit from laboratories across the UK between November 2007 305 
and December 2014. Over this study period 741 OXA-48-like-positive isolates were obtained 306 
from 536 patients across all UK regions.  307 
The majority of isolates were from clinical specimens, predominantly urines. All isolates were 308 
resistant to ≥2 classes of antibiotics and most were non-susceptible at EUCAST breakpoints 309 
to at least one of the three carbapenems tested. A high rate of susceptibility was maintained 310 
only to colistin (91%), with amikacin (74% susceptible) and tigecycline (68%) next in rank 311 
order. High levels of resistance to the third-generation cephalosporins, ceftazidime and 312 
cefotaxime, could be attributed to the co-carriage of ESBL/AmpC enzymes in 76% of 313 
sequenced isolates. There was huge variation in susceptibility to other antibiotics tested in 314 
this study, attributable to the presence of a plethora of other resistance genes, as identified 315 
in the WGS analyses (Table 2), sometimes including other carbapenemase genes - 5% 316 
(34/741) of isolates with OXA-48-like enzymes also harboured either a blaNDM (33/741) or 317 
blaVIM (1/741) allele. It follows that there can be no ‘standard’ antibiotic regimen for the 318 
treatment of infections caused by OXA-48-like producers without additional susceptibility 319 
testing and/or resistance gene data, although ceftazidime-avibactam shows promise based 320 
on in vitro data.23 Although colistin, tigecycline and amikacin retained the highest levels of 321 
susceptibility their individual indications may make them unsuitable for the treatment of some 322 
infections. For example tigecycline cannot be used for the treatment of urinary tract 323 
infections24 and colistin use has been associated with both neuro- and nephrotoxicity.25   324 
At the time of writing there are 14 known OXA-48-like variants, 11 of them CHDLs, and WGS 325 
analysis of 351 non-duplicate UK isolates identified five of the CHDL types. OXA-48 was by 326 
far the most common variant, found in two-thirds (235/351) of isolates. The earliest OXA-48-327 
positive isolate identified in the UK was obtained in 2007 from a patient who had recently 328 
been hospitalised in Turkey; this isolate was shown here to be an ST147 K. pneumoniae 329 
carrying a plasmid with >99% identity to pOXA-48a. pOXA-48a has been implicated in early 330 
OXA-48 dissemination in Turkey.15, 26  331 
A travel history was available for only 24% of patients, of whom 10% had documented travel 332 
to 18 different countries/islands, several of which have previously reported outbreaks 333 
involving bacteria with OXA-48-like enzymes.2, 4, 5, 27 All five patients with reported travel to 334 
Turkey and 6/7 with travel to other Middle Eastern or North African countries whose isolates 335 
were analysed by WGS were found to carry organisms with blaOXA-48, as repeatedly found in 336 
Turkey.26, 27 By contrast, both OXA-181 and OXA-232 have been associated with the Indian 337 
subcontinent,12, 28 and were found in 12/13 sequenced isolates from patients reporting travel 338 
to India, Pakistan or Sri Lanka. These data further underscore the role that international 339 
travel may play in carbapenemase dissemination. Notably four K. pneumoniae with OXA-48-340 
like enzymes were from patients transferred to the UK for intensive care treatment of injuries 341 
received during the Libyan ’Emergency’ of 2011. 342 
Forty-four percent (154/351) of sequenced isolates, and 153/235 of those with classical 343 
blaOXA-48  possessed DNA with >99% sequence identity to pOXA-48a, an approx. 62 kb 344 
IncL/M plasmid first associated with blaOXA-48, in Turkey and North Africa and now with 345 
multiple polyclonal and cross species outbreaks.15  pOXA-48a-like sequences were found 346 
here in multiple species and sequence types. Except for one isolate with blaOXA-245 these all 347 
carried blaOXA-48. The demonstration of both the broad range and success of this plasmid 348 
supports an earlier and much smaller analysis where we found IncL/M OXA-48 plasmids 349 
amongst several enterobacterial species and STs.10 Of the remaining 197 isolates 350 
sequenced, 68 carried DNA with >99% identity to one of three plasmids: pOXA-232 (32/68), 351 
pOXA181 (30/68) or pKP3-A (6/68). pOXA-232 and pKP3-A are ColE-like plasmids, of 352 
approx. 6 kb and 7.6 kb respectively, originally discovered in E. coli and K. pneumoniae 353 
isolates obtained from patients following hospitalisation in India.28, 29 All of the 32 sequenced 354 
isolates harbouring blaOXA-232 and six of 69 isolates with blaOXA-181 contained sequences with 355 
>99% sequence identity to pOXA-232 and pKP3-A respectively. Thirty further isolates with 356 
OXA-181 enzymes were shown to carry DNA with  >99% sequence identity to pOXA181, an 357 
IncX3 plasmid of approx. 51.5 kb that was first found in an E. coli ST410 isolate obtained 358 
from the blood sample of a patient in China who had no history of travel to the Indian 359 
subcontinent.30  360 
We found blaOXA-48-like genes in multiple species and STs and also that there were some 361 
clones that were particularly successful as a vehicle for blaOXA-48-like dissemination. In K. 362 
pneumoniae some STs (such as ST14 and ST147) were associated with multiple OXA-48-363 
like plasmids, indicating the success of the ST but not indicating expansion of a specific 364 
clone/plasmid pairing. Although K. pneumoniae ST395 has been associated with outbreaks 365 
in Europe and Morocco,13 we found only two representatives among those sequenced and 366 
these harboured different OXA-48-like variants, blaOXA-48 and blaOXA-181, in different genetic 367 
environments; one in a pKP3-A sequence and the other in an unidentified environment.  368 
Rather alarmingly, 16% of isolates were submitted from a single hospital, hospital A, 369 
representing at least six species and 33 STs. Within the sixty-one isolates from hospital A 370 
that were sequenced most (54/61) harboured pOXA-48a sequences. This suggests the local 371 
spread of pOXA-48a amongst different genera, species and STs within this hospital and is 372 
indicative of the success of pOXA-48a in dissemination. 373 
In contrast to the ST diversity among K. pneumoniae isolates with OXA-48-like enzymes 374 
ST38 accounted for almost half of all the sequenced E. coli isolates with OXA-48-llike 375 
enzymes (53/114). ST38 has previously been associated with blaCTX-M carriage in multiple 376 
countries.31 Plasmid mapping could not establish a location for blaOXA-48 in most (50/53) of 377 
these isolates. In a previous study10 the authors failed to obtain any plasmid transformants 378 
from ST38 isolates and, more recently, it was reported that blaOXA-48 and blaOXA-244 can be 379 
chromosomally-encoded in ST38 isolates.32 This may apply here, but establishing this would 380 
require utilisation of longer read sequencing techniques (e.g. PacBio and MinION). 381 
In summary, this study has shown an increase in OXA-48-like enzymes in the UK over a 382 
seven-year period. We suggest that the accumulation of OXA-48-like carbapenemases 383 
within the UK is due to repeated import, coupled with both the dissemination of successful 384 
plasmids, notably pOXA-48a and the spread of successful clones (e.g. E. coli ST38); the 385 
linkage to plasmid spread was especially strong.   386 
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Table 1. Sources of OXA-48-like-positive isolates. 521 
 Hospital setting   
Species Urines Screening 
swabs 
Blood 
cultures and 
line tips 
Respiratory Tissue and 
fluid 
Faeces/Rectal 
swabs 
Not known GP urines Total 
K. pneumoniae 91 27 48 28 58 110 8 15 385 
E. coli 47 22 18 7 28 58 2 25 207 
Enterobacter spp. 6 15 9 1 9 16 10 1 67 
K. oxytoca 2 2 7 0 2 6 0 4 23 
Citrobacter spp.  5 2 1 0 0 4 0 0 12 
S. marcescens 0 0 0 0 1 0 0 0 1 
R. ornithinolytica 0 0 0 0 0 1 0 0 1 
other spp.a 0 0 0 2 2 1 0 0 5 
Total 151 68 83 38 100 196 20 45 701 
 522 
 Unknown setting  
Species Urines Screening 
swabs 
Blood 
cultures and 
line tips 
Respiratory Tissue and 
fluid 
Faeces/Rectal 
swabs 
Not known Total 
K. pneumoniae 9 0 0 1 7 4 2 23 
E. coli 8 0 0 0 2 1 0 11 
Enterobacter spp. 1 0 0 0 0 0 0 1 
K. oxytoca 0 0 0 1 0 0 0 1 
Citrobacter spp. 1 0 0 0 0 1 0 2 
S. marcescens 0 0 0 0 1 0 1 2 
Total 19 0 0 2 10 6 3 40 
a- other species comprise P. aeruginosa (n=3) and Shewanella spp. (n=2). 523 
 524 
 525 
Table 2. Characteristics of 351 non-duplicate isolates that were subjected to WGS. 526 
  Carbapenemases   Other resistance genes 
Species No. of 
isolates 
OXA-48-like 
alleles (no.) 
OXA + NDM alleles 
(n=13) 
STs (no. if >1) 
 
Replicons 
 
Beta-lactamases 
(variants) 
Aminoglycoside 
resistance genes 
Others 
K. pneumoniae 163 OXA-48(86), 
OXA-181(31), 
OXA-232(24), 
OXA-245(1), 
OXA-484(5) 
OXA-48+NDM-1(3), 
OXA-181+NDM-
1(5), OXA-
232+NDM-1(8) 
11(10), 14(27), 15(4), 16(6), 
17, 25(2), 35, 36, 39, 43, 
45(4), 48(2), 101(13), 104, 
105, 111, 133(2), 147(17), 
152, 187(2), 231(18), 253, 
294, 299, 307(7), 323, 327, 
336(3), 359, 392(3), 395(2), 
405(2), 461(2), 659, 685, 
709, 831(2), 922, 985, 1141, 
1164, 1473(5), 1680(2), 
1819, 1821, 1825, 1827, 
1834, 2205 
 
A/C, 
ColKP3, 
FIA, FIB, 
FII, HI2, 
L/M, X3 
blaTEM-1, blaSHV 
(1,11,28,33,39,75,76,1
00,103,159), blaCTX-M 
(14,15,16), blaOXA 
(1,9), blaDHA-1, blaCMY-4 
strA, strB, aadA1, 
aadA2, aadA3, 
aadA5, armA, 
aac(3)-lla, aac(3)-
lld, aac(6’)lb-cr, 
rmtF 
oqxA, oqxB, qnrB1, 
qnrS1, qnrB66, arr-2, 
arr-3, sul1, sul2, fosA, 
mphA, msrE, ereA, 
ereB, ereC, ermB, 
mdfA, dfrA1, dfrA5, 
dfrA7, dfrA12, dfrA14, 
catA1, catB3, cmlA1, 
sat2, tetA, tetD 
E. coli 114 OXA-48(74), 
OXA-181(30), 
OXA-244(10) 
 10(4), 28, 38(53), 58, 59, 69, 
73, 83, 95, 127, 131, 167, 
205(2), 224, 227(2), 354(2), 
361, 399(3), 401, 405(4), 
410(12), 428, 648, 681, 
940(3), 1170, 1284(2), 1431, 
1722, 2139, 2164, 2179, 
3221, 3541, 6328, 6329, 
6330 
 
B/O, FIA, 
FIB, FII, 
HI2, K, 
L/M, X3 
blaTEM (1,33,169,190), 
blaCTX-M 
(14,15,24,27,82), 
blaOXA (1,10), blaCMY 
(2,42,44,54,59,61) 
strA, strB, aadA1, 
aadA2, aadA3, 
aadA5, aadA23, 
aac(3)-lld, aac(3)-
lla, aph(6)-ld, 
aac(6’)lb-cr, rmtB 
qnrB1, qnrS1, qepA, 
mdfA, mphA, ermB, 
msrE, dfrA1, dfrA5, 
dfrA7, dfrA12, dfrA14, 
dfrA17, fosA, sul1, 
sul2, catA1, cmlA1, 
floR, sat2, tetA, tetD 
 
E. cloacae 
complex 
42 OXA-48(40) OXA-48+NDM-1(2)  FIB, FII, 
HI1, L/M 
blaTEM-1, blaOXA-1, blaSHV 
(5,12), blaCTX-M 
(9,15,82), blaACT 
(7,14,15,16) 
strA, strB, aadA2, 
aadA3, aadA12, 
aac(3)-lla, ant(2”)-
la, aac(6’)-llc, 
aac(6’)lb-cr 
qnrA1, qnrB1, qnrS1, 
ereA, mphA, dfrA12, 
dfrA14, dfrA16, dfrA18, 
fosA, sul1, sul2, catA1, 
catA2, tetA, tetD 
 
K. oxytoca 13 OXA-48(13)  27(4), 36, 95, 168, 176(6) 
 
FII, HI2, 
L/M 
blaTEM-1, blaOXY 
(1,2,5,6) 
strA, strB, aac(3)-
lla 
qnrA1, mphA, dfrA18, 
sul1, tetD, tetK 
 
C. freundii 11 OXA-48(10) OXA-181+NDM- ND A/C, FIB, blaTEM-1, blaCMY-48,  qnrB12, dfrA7, sul1, 
527 
1(1)  FII, L/M blaMAL-1 sul2, tetD 
Other 
Enterobacter 
spp. 
5 OXA-48(5)  45(3), 51, 66(5), 90, 93(3), 
104(4), 106, 108(17),135, 
145, 268, 269, 279(3) 
H, L/M, N blaTEM-1, blaCTX-M-14, 
blaACT-37, blaSHV-12 
strA, strB, aadA1, 
aadA2, aph(6)-ld, 
aac(6’)-llc, 
aph(3’)-Vib 
qnrA1, ereA, dfrA18, 
floR, tetA, sul1, sul2, 
sul3 
S. marcescens 2 OXA-48(2)  ND L/M blaCTX-M (14,82) strA, strB, aph(3’)-
Vib 
 
P. aeruginosa 1 OXA-181(1)  773  blaPAO, blaOXA-50 aac(3)-Ie, aph(3')-
IIb, aadA1 
catB7, dfrB5, sul1 
Table 3. MIC distributions for OXA-48-like-positive isolates (n=741). 528 
    Number of isolates with MIC (mg/L)  
Carbepenemase 
gene(s) 
Isolates Antibiotic 
(range tested, 
mg/L) 
EUCAST 
breakpoints 
≤S/>R 
≤0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 NA %S 
OXA-48-like Enterobacteriaceae Ertapenem 
(0.125-16) 
≤0.5/>1   4 15 53 124 147 351a    7 <1 
other spp.c            6 NA 
NDM + OXA-48-like Enterobacteriaceae        33a     0 
VIM + OXA-48-like Enterobacteriaceae          1a     0 
OXA-48-like Enterobacteriaceae Imipenem 
(0.06-128) 
≤2/>8  5 28 92 186 180 98 47 22 20 17a 6 45 
other spp.c   1   1   1 1 2a  17 
NDM + OXA-48-like Enterobacteriaceae      1 4 6 3 7 12a  0 
VIM + OXA-48-like Enterobacteriaceae           1a    0 
OXA-48-like Enterobactericaeae Meropenem 
(0.06-32) 
≤2/>8 7b 38 105 138 110 69 35 81 112a   6 57 
other spp.c 1b   1    1 3a    33 
NDM + OXA-48-like Enterobactericaeae       1 4 28a    0 
VIM + OXA-48-like Enterobacteriaceae           1a    0 
OXA-48-like Enterobactericaeae Ceftazidime 
(0.125-256) 
≤1/>4 14b 57 69 86 31 28 26 23 47 83 231a 6 33 
 other spp.c  2b    2 2       33 
NDM + OXA-48-like Enterobactericaeae            33a  0 
VIM + OXA-48-like Enterobacteriaceae            1a  0 
OXA-48-like Enterobactericaeae Cefotaxime 
(0.125-256) 
≤1/>2 1b 3 28 48 40 45 42 23 22 33 405a 11 12 
 other spp.c  1b           5 100 
NDM + OXA-48-like Enterobactericaeae            33a  0 
VIM + OXA-48-like Enterobacteriaceae            1a  0 
OXA-48-like Enterobactericaeae Amikacin     
(0.5-64) 
≤8/>16   26b 138 186 124 58 47 30 86a  6 77 
other spp.c    2  1   1 2a   50 
NDM + OXA-48-like Enterobactericaeae     2 2 2   27a   18 
VIM + OXA-48-like Enterobacteriaceae            1a   0 
OXA-48-like Enterobactericaeae Gentamicin 
(0.125-32) 
≤2/>4 3b 55 175 85 10 11 10 22 324a   6 47 
other spp.c  1   1 1 2 1     33 
NDM + OXA-48-like Enterobactericaeae   1      32a    3 
VIM + OXA-48-like Enterobacteriaceae           1a    0 
OXA-48-like Enterobactericaeae Tobramycin 
(0.125-32) 
≤2/>4 1b 17 119 114 29 36 59 87 230a   9 40 
other spp.c    1 1  1  3a    33 
NDM + OXA-48-like Enterobactericaeae        5 28a    0 
VIM + OXA-48-like Enterobacteriaceae           1a    0 
OXA-48-like Enterobactericaeae Ciprofloxacin 
(0.125-8) 
≤0.5/>1 191b 45 33 24 11 37 343a     17 39 
other spp.c 1b   1   4a      17 
NDM + OXA-48-like Enterobactericaeae       31a     2 0 
VIM + OXA-48-like Enterobacteriaceae         1a      0 
OXA-48-like Enterobactericaeae Colistin       
(0.5-32) 
≤2/>2   397b 204 20 11 16 13 21a   19 91 
other spp.c   2b 2 1 1       83 
NDM + OXA-48-like Enterobactericaeae   19b 12 1 1       97 
VIM + OXA-48-like Enterobacteriaceae      1         100 
OXA-48-like Enterobactericaeae Tigecycline 
(0.25-16) 
≤1/>2  185b 140 144 118 65 24 6a    19 69 
other spp.c  1b   1       4 50 
NDM + OXA-48-like Enterobactericaeae  8b 3 6 12 3  1a     52 
VIM + OXA-48-like Enterobacteriaceae         1      0 
S, susceptible; R, resistant; NA, not available. 529 
The dotted vertical lines indicate intermediate breakpoints and the solid vertical lines indicate resistant breakpoints. 530 
aMIC greater than or equal to indicated value. 531 
bMIC less than or equal to indicated value. 532 
cother spp. comprise Pseudomonas aeruginosa and Shewanella spp.. 533 
 534 
